Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

Imad Uthman, MD, MPH, and Munther Khamashta, MD, PhD  |  Issue: February 2014  |  

Dr. Uthman is head of the division of rheumatology, faculty of medicine at American University of Beirut in Lebanon, and Dr. Khamashta is director of the Graham Hughes Lupus Research Laboratory in the division of women’s health at King’s College of London’s Rayne Institute in London.

References

  1. Hughes GR. Put Hughes syndrome on your radar. The Rheumatologist. 2007;1:20-21.
  2. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983;287:1088-1089.
  3. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The “primary” antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore). 1989;68:366-374.
  4. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-1027.
  5. Mehdi AA, Uthman I, Khamashta MA. Antiphospholipid syndrome: Pathogenesis and a window of treatment opportunities in the future. Eur J Clin Invest. 2010;40:451-464.
  6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-1509.
  7. Uthman IW, Khamashta MA. Livedo racemosa: A striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 2006;33:2379-2382.
  8. Gray JM, Khamashta MA. Antiphospholipid syndrome: Coming of age. Reumatol Clin. 2011;7:151-153.
  9. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
  10. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis. 2012;71:242-244.
  11. Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003;62:1127.
  12. Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford). 2013;52:1358-1367.
  13. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033-1044.
  14. Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol. 2001;13:377-382.
  15. Matsuura E, Shen L, Matsunami Y, et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus. 2010;19:379-384.
  16. Banzato A, Pozzi N, Frasson R, et al. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res. 2011;128:583-586.
  17. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206-218.
  18. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504-512.
  19. Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: Role in pregnancy losses and thrombosis. Lupus. 2010;19:460-469.
  20. C Parashari U, Singh R, Parihar A, Aga P, Yadav R. Diagnostic role of magnetic resonance angiography in Swyer James syndrome: Case series of two cases. Lung India. 2010;27:161-163.
  21. Espírito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol. 2010;38:307-318.
  22. Silver RM, Parker CB, Reddy UM, et al. Antiphospholipid antibodies in stillbirth. Obstet Gynecol. 2013;122:641-657.
  23. Erkan D, Lockshin MD, APS ACTION members. APS ACTION–AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. Lupus. 2012;21:695-698.
  24. Pengo V. APS–controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127 Suppl 3:S51-S52.
  25. Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, et al. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol. 2011;38:1026-1032.
  26. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: The new anticoagulants? Lupus. 2010;19:486-491.
  27. Pericleous C, Ioannou Y. New therapeutic targets for the antiphospholipid syndrome. Expert Opin Ther Targets. 2010;14:1291-1299.
  28. Giles I, Khamashta MA, D’Cruz D, Cohen H. A new dawn of anticoagulation for patients with antiphospholipid syndrome? Lupus. 2012;21:1263-1265.
  29. Scoble T, Wijetilleka S, Khamashta MA. Management of refractory anti-phospholipid syndrome. Autoimmun Rev. 2011;10:669-673.
  30. Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70:675-682.
  31. Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464-471.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    APS: What Rheumatologists Should Know about Hughes Syndrome

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…